| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8814451 | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging | 2018 | 47 Pages |
Abstract
This is the first sham-controlled investigation to demonstrate, in two populations, that VMPFC cTBS can attenuate neural reactivity to drug and alcohol cues in frontostriatal circuits. These results provide an empirical foundation for future clinical trials that may evaluate the efficacy, durability, and clinical implications of VMPFC cTBS to treat addictions.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Tonisha E. Kearney-Ramos, Logan T. Dowdle, Daniel H. Lench, Oliver J. Mithoefer, William H. Devries, Mark S. George, Raymond F. Anton, Colleen A. Hanlon,